-
EHA Reflections | Professor Lei Fan’s Late-Breaking Oral Presentation: World’s First In Vivo Dual-Target CAR-T LB2501 Reshapes the Treatment Landscape for Lymphoma
At the 2026 European Hematology Association (EHA) Congress, the field of cellular therapy witnessed a landmark breakthrough. During a prestigious Late-Breaking Oral Session, Professor Lei Fan from Jiangsu Provincial People’s Hospital presented the first-ever clinical proof-of-concept data for LB2501, the world’s first in vivo CD19/CD20 dual-target CAR-T therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma…
-
A New Era Begins: World’s First Bispecific ADC Iza-bren Approved, Redefining Cancer Treatment and Delivering Early Benefits to Chinese Patients
In June 2026, China’s National Medical Products Administration (NMPA) approved iza-bren (brand name: Yizekang®; generic name: Loncastuximab Eglonatamab), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) independently developed by Biokin Pharmaceutical. The approval is for the treatment of patients with relapsed or metastatic nasopharyngeal carcinoma (NPC) following prior therapy.
-
EHA 2026 | Dr. Yajing Zhang: Moving from Empirical Treatment Toward Mechanism-Driven Precision Stratification in Relapsed/Refractory Hematologic Malignancies
The 2026 European Hematology Association (EHA 2026) Congress was held in Stockholm, Sweden, from June 11–14, 2026. Dr. Yajing Zhang and colleagues from Beijing GoBroad Boren Hospital presented three studies at this year’s meeting, focusing on two critical questions in the management of relapsed/refractory hematologic malignancies.
-
EHA Reflections | Professor Erlie Jiang: Advancing Precision Transplantation and Building a Comprehensive Lifecycle Management System
At the 2026 European Hematology Association (EHA) Congress, the team led by Professor Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented an impressive portfolio of 27 research studies spanning multiple dimensions of hematopoietic stem cell transplantation (HSCT).
-
Towards a “Chemo-Sparing” Era: I-SPY 2.2 Study Explores the Precision Benefits of the Combination of Immune Bispecific Antibody and ADC in High-Risk HER2-Negative Breast Cancer
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Ciara Catherine O’Sullivan from Mayo Clinic, representing the I-SPY 2.2 collaborator group, announced the neoadjuvant treatment results of Rilvegostomig (an anti-PD-1/TIGIT bispecific antibody) combined with Trastuzumab Deruxtecan (T-DXd) for early-stage high-risk HER2-negative breast cancer. Based on innovative Response Predictive Subtypes (RPS), the study…
-
rwPFS Reaches 10.5 Months! PALMARES-2 Study Confirms Survival Benefit of Continuous Treatment Beyond Progression Following First-Line ET+CDK4/6i
At a recent international academic conference on breast cancer, Professor Claudio Vernieri from the University of Milan and the Fondazione IRCCS Istituto Nazionale dei Tumori shared the latest results of the multicenter, real-world study PALMARES-2. The study focuses on patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). It explores…
-
Moving from Relapsed/Refractory to Early Treatment: Professor Cyrille Touzeau Interprets the EMN34 Study, Elranatamab Opens a New Chapter in Precision Intervention for HR SMM
In the evolution of treatment for Multiple Myeloma (MM), moving highly effective therapies forward to the early stages of the disease has become a current research hotspot. For patients with High-Risk Smoldering Multiple Myeloma (HR SMM), whether early active intervention can delay or even prevent its transformation into active myeloma is a focus of clinical…
-
Breaking the Deadlock with “Synthetic Lethality” Targeting MTAP Deficiency: AZD3470 Achieves 58% ORR in Multi-line Drug-Resistant Hodgkin Lymphoma
In the field of relapsed/refractory classical Hodgkin lymphoma (R/R cHL), although the application of immune checkpoint inhibitors (such as anti-PD-1) and antibody-drug conjugates (such as Brentuximab Vedotin, BV) has significantly improved patient prognosis, clinical challenges remain severe for patients who fail multiple lines of therapy. Recently, at an international academic conference, Professor Enrico Derenzini, on…
Connecting Medical Expertise through Media